What question did this study set out to answer?

The aim is to analyze the clinical features and treatment outcomes in patients with SLC52A3-related Brown-Vialetto-Van Laere syndrome.

May 2, 2026

SLC52A3-related Brown-Vialetto-Van Laere syndrome: a large cohort from the Arabian Peninsula.

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial shows the impact of riboflavin treatment on outcomes in SLC52A3-related BVVL patients, suggesting early intervention is crucial.

The aim is to analyze the clinical features and treatment outcomes in patients with SLC52A3-related Brown-Vialetto-Van Laere syndrome.
Retrospective review of 23 patients with genetically confirmed BVVL diagnosis from two tertiary centers.
Assessment of clinical features and treatment effects of riboflavin over a median follow-up of 4 years.
11/13 symptomatic patients showed significant or near-total recovery with residual symptoms.
9/10 pre-symptomatic patients remained symptom-free after treatment with riboflavin.
2 symptomatic patients achieved complete resolution of symptoms after riboflavin treatment.

Shamsi et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial shows the impact of riboflavin treatment on outcomes in SLC52A3-related BVVL patients, suggesting early intervention is crucial.